Aug 07, 2025
Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity
Aug 07, 2025
Lilly reports second-quarter 2025 financial results and raises guidance
Jul 31, 2025
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease
Jul 30, 2025
Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
Jul 25, 2025
Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease
Jul 25, 2025
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Jul 24, 2025
Lilly and Verve announce expiration of Verve tender offer
Jul 24, 2025
Lilly confirms date and conference call for second-quarter 2025 financial results announcement
Jul 09, 2025
FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease
Jun 23, 2025
Lilly declares third-quarter 2025 dividend
Jun 22, 2025
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
Jun 21, 2025
Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
Jun 17, 2025
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Jun 16, 2025
Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions
Jun 02, 2025
Lilly presents first clinical data for its investigational, next-generation FRa targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting
Jun 02, 2025
Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference
May 29, 2025
Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions
May 27, 2025
Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics
May 22, 2025
Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
May 21, 2025
Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease